Tendyne Raises $25 Million
in Series C

Proceeds will be used for validation of Tendyne’s novel Transcatheter Mitral Valve Implant to treat mitral regurgitation, including forthcoming clinical trials.

READ MORE

©2014 Tendyne Holdings, Inc.

Tendyne’s products are not approved for investigational use or sale in the United States.